• OncoZenge flagged new findings from a UCLA patient engagement study on oral mucositis pain during head and neck radiotherapy.
• Results will be presented in the future at the 2026 ASTRO Annual Meeting in Boston on Sept. 28.
• Patients reported a heavy pain burden, with existing pain options often failing to deliver adequate relief due to side effects.
• Study feedback favored a new topical treatment with fast onset, longer-lasting relief, and minimal systemic side effects.
• OncoZenge said the insights supported the design of its Phase III program for BupiZenge.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncozenge AB published the original content used to generate this news brief on September 09, 2026, and is solely responsible for the information contained therein.